Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 5/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712456 | 0.86 | CYP2C9 (0.42) | CYP2C9LMNAPOLBERN1PTGS2 | |
| SCHEMBL457853 | 0.83 | CYP2A6 (0.47) | LMNAERN1SMN1; SMN2TTKCYP2A6 | |
| SCHEMBL15363784 | 0.81 | CYP2C9 (0.39) | CYP2C9LMNAPOLBPTGS2PTGS1 | |
| SCHEMBL458722 | 0.81 | ERN1 (0.45) | CYP2C9ERN1SMN1; SMN2TTKCYP2A6 | |
| SCHEMBL16712516 | 0.81 | ERN1 (0.42) | CYP2C9LMNAERN1SMN1; SMN2TTK | |
| SCHEMBL456610 | 0.80 | ERN1 (0.53) | ERN1PTGS2PTGS1SMN1; SMN2TTK | |
| SCHEMBL456274 | 0.79 | FABP1 (0.41) | CYP2C9PTGS2PTGS1 | |
| SCHEMBL16712457 | 0.77 | CYP2C9 (0.42) | CYP2C9LMNAPOLBPTGS2PTGS1 | |
| SCHEMBL15363612 | 0.76 | CYP2C9 (0.43) | CYP2C9LMNAPOLBPTGS2PTGS1 | |
| SCHEMBL458823 | 0.75 | NPC1 (0.48) | CYP2C9LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153996-B | As quinoline and the quinoxaline derivatives of kinase inhibitor | UCB PHARMA S.A. (BE) | 2016-01-27 | — | — | CN | disclosed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| CN-103153996-A | Quinoline and quinoxaline derivatives as kinase inhibitors | UCB PHARMA SA | 2013-06-12 | — | — | CN | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | CYP2C9 2715/4885LMNA 1912/4885POLB 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.